A paper outlining MHRA’s intentions to make it quicker and easier to get rare disease therapies tested, manufactured and approved in the UK.
Similar Posts
Guidance: Operational Information Sharing
Guidance for Marketing Authorisation (MA) applicants on providing consent to share operational information during the MA application process.
Decision: Advertising Investigations: January 2026
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Field Safety Notices: 09-13 February 2026
A list of Field Safety Notices: 09-13 February 2026
If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy
MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines in latest blow to criminal network
Officers from the MHRA’s Criminal Enforcement Unit (CEU) have raided two separate premises as part of an ongoing investigation into an organised criminal network involved in the manufacture and sale of unlicensed weight loss medicines.
Nirogacestat hydrobromide approved to treat desmoid tumours
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.